Literature DB >> 22345999

A novel mutation (4040-4045 nt. delA) in exon 14 of the factor VIII gene causing severe hemophilia A.

Habib Onsori1, Mohammad Ali Hosseinpour Feizi, Abbas Ali Hosseinpour Feizi.   

Abstract

Hemophilia A is an X-linked congenital bleeding disorder caused by Factor VIII deficiency. Different mutations including point mutations, deletions, insertions and inversions have been reported in the FVIII gene, which cause hemophilia A. In the current study, with the use of conformational sensitive gel electrophoresis (CSGE) analysis, we report a novel 1-nt deletion in the A6 sequence at codons 1328-1330 (4040-4045 nt delA) occurring in exon 14 of the FVIII gene in a seven-year-old Iranian boy with severe hemophilia A. This mutation that causes frameshift and premature stop-codon at 1331 has not previously been reported in the F8 Hemophilia A Mutation, Structure, Test and Resource Site (HAMSTeRS) database.

Entities:  

Keywords:  Conformational sensitive gel electrophoresis; Hemophilia A; deletion; factor VIII; frameshift; novel mutation

Year:  2011        PMID: 22345999      PMCID: PMC3276996          DOI: 10.4103/0971-6866.92095

Source DB:  PubMed          Journal:  Indian J Hum Genet        ISSN: 1998-362X


Introduction

Hemophilia A is an inherited deficiency of coagulation factor VIII (FVIII). It is caused by mutations in the factor VIII gene and its incidence is estimated to be 1:5,000–10,000 in men.[12] Deleterious mutations in the FVIII gene have been demonstrated to reduce either or both activity and circulating plasma level of FVIII protein and thus cause disease.[3] Point mutations are the most prevalent type of defect, probably underlying the disease in 90–95% of patients. Deletions are the second most common gene defects (5–10% of patients).[4] The identification of carriers of the disease is an essential part of genetic counseling and prenatal diagnosis.[5]

Case Report

A seven-year-old boy (HA11) was referred to our hospital in 2008 due to gum bleeding. Severe bleeding with other medical inspections showed probability of severe hemophilia A. In order to assess the causal mutation, genomic DNA was extracted from 2.5 mL of EDTA anticoagulated peripheral blood by SDS-proteinase K according to Sambrook et al.[6] Polymerase chain reaction (PCR) of genomic DNA from the patient and a normal male subject for all 26 exons with exon-intron boundaries regions were performed in 37 segments with the use of same sets of primers as reported by Steve Keeney.[7] PCR reactions were carried out in 25 μL reaction mixture containing 1 × PCR buffer, 1.5 mM MgCl2, 0.2 mM dNTP, 10 pmoles of each primer, 0.5 U of Taq DNA polymerase and about 1μg of genomic DNA on a Genius Thermal Cycler. After initial denaturation for 2 min at 95°C, 30 cycles of 30 s at 94°C, annealing for 40 s at 59°C and extension for 30 s at 72°C, a final extension for 5 min at 72 °C followed. The amplified fragments were detected on 1.5% agarose gel by ethidium bromide staining. The PCR-amplified fragments longer than 400bp were subjected to conformational sensitive gel electrophoresis (CSGE) and the fragments shorter than 400bp were subjected to single-stranded conformational polymorphism (SSCP) analysis. CSGE was performed on 10% acrylamide gel with 1,4-bis-acrolyl piperazine (99:1), 15% formamide and 10% ethylene glycol in 0.5× TTE buffer (1x TTE = 89 mmol/L tris, 28.5 mmol/L Taurin and 0.2 mmol/L EDTA). Ammonium persulfate and N,N,N’,N’- tetramethylethylene diamine (TEMED) were used to catalyze polymerization.[8] Samples (heteroduplexes) were prepared by mixing 2 μl of the PCR product from a control DNA with 2 μl of the PCR product of the corresponding fragment, and then incubated at 98°C for 2 min, followed by 10 min at 65°C and 20 min at 37°C. After this step, 5 μl of 10x loading buffer (30% glycerol, 0.25% xylene cyanol, and 0.25% bromophenol blue in distilled water) was added to each sample, which was then applied to the gel. Prior to loading, the gel was electrophoresed at 700 V for 0.5-1h. After loading 5 μl of heteroduplexed amplicons, electrophoresis was carried out at 300 V for 16 h. The gel was stained with ethidium bromide for 15 min. Detection was carried out by UV doc apparatus. SSCP was performed as described previously.[9] PCR products showing abnormal electrophoretic mobility on SSCP or CSGE gel were sequenced by Kawsar Company and analyzed by sequencing-analysis Chromas Lite 2.01 software. The sequences were compared with the wild type.

Results

In this study, we detected a novel single nucleotide deletion occurring in exon 14 of the FVIII gene in a seven-year-old Iranian boy with severe hemophilia A (FVIII: C <1%). Among all amplified fragments, only PCR product of exon 14D with 595bp long displayed unmatched shift in CSGE [Figure 1]. Sequence analysis of exon 14D PCR product showed a novel mutation [Figure 2]. This mutation due to 1-nt deletion in the A6 sequence at codons 1328-1330 (4040-4045 nt delA) causes frameshift and premature stop- codon (termination at 1331). This new mutation was recorded in GenBank (NCBI) with accession number EU 598148.1.
Figure 1

Part of CSGE gel showing the migration pattern of exon 14D amplified fragments. Fragments with abnormal migration patterns are marked by arrow. N: normal control and 1, 2, 3, 4 (HA11), 5, 6, 7, 8, 9 different hemophilia A patients.

Figure 2

DNA sequencing profile of the FVIII gene (exon 14D) from the patient and normal control. This figure indicates 1nt (A) deletion in the A6 sequence at codons 1328-1330 in the patient DNA sequence that causes premature termination codon at 1331. Underlining indicates the position of nucleotide deletion.

Part of CSGE gel showing the migration pattern of exon 14D amplified fragments. Fragments with abnormal migration patterns are marked by arrow. N: normal control and 1, 2, 3, 4 (HA11), 5, 6, 7, 8, 9 different hemophilia A patients. DNA sequencing profile of the FVIII gene (exon 14D) from the patient and normal control. This figure indicates 1nt (A) deletion in the A6 sequence at codons 1328-1330 in the patient DNA sequence that causes premature termination codon at 1331. Underlining indicates the position of nucleotide deletion.

Discussion

Small deletions and insertions in the coding region of the gene, in most cases, resulting in frameshifts, and more than half of them are in the large exon 14. These mutations with only few exceptions are leading to a severe clinical phenotype.[10] According to the hemophilia A database (http://europium.csc.mrc.ac.uk), from identified 175 small deletion (<50bp) in exon 14 of the factor VIII gene, 91 cases (52%) are 1A deletion that cause severe hemophilia A in all of them. Due to the nature of the sequence alteration, these mutations are expected to be easily detected by different screening approaches with a high rate of sensitivity.[10] In this study, we used CSGE method for mutation detection. It has the advantages of being simple and relatively rapid to perform and does not require the use of radiolabel. Despite this apparent simplicity, the technique requires a great deal of skill, both technical and interpretive, to achieve good sensitivity. So, this study shows that use of CSGE and direct sequencing can be useful for point mutation recognition of the FVIII gene.
  8 in total

Review 1.  [Molecular diagnosis of haemophilia A in clinical practice].

Authors:  D Habart
Journal:  Cas Lek Cesk       Date:  2005

2.  Rapid identification of female haemophilia A carriers with deletions in the factor VIII gene by quantitative real-time PCR analysis.

Authors:  Eduardo F Tizzano; María J Barceló; Manel Baena; Mónica Cornet; Adoración Venceslá; José Mateo; Jordi Fontcuberta; Montserrat Baiget
Journal:  Thromb Haemost       Date:  2005-09       Impact factor: 5.249

3.  The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4.

Authors:  G Kemball-Cook; E G Tuddenham; A I Wacey
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

4.  Prevalence of small rearrangements in the factor VIII gene F8C among patients with severe hemophilia A.

Authors:  Nadja Bogdanova; Arseni Markoff; Hartmut Pollmann; Ulrike Nowak-Göttl; Roswith Eisert; Bernd Dworniczak; Antonin Eigel; Jürgen Horst
Journal:  Hum Mutat       Date:  2002-09       Impact factor: 4.878

Review 5.  Blood coagulation factor VIII: An overview.

Authors:  G M Bhopale; R K Nanda
Journal:  J Biosci       Date:  2003-12       Impact factor: 1.826

6.  Identification of a novel missense mutation in exon 4 of the human factor VIII gene associated with sever hemophilia A patient.

Authors:  Habib Onsori; Mohammad Ali Hosseinpour; Sheideh Montaser-Kouhsari; Mohammad Asgharzadeh; Abbas Ali Hosseinpour
Journal:  Pak J Biol Sci       Date:  2007-12-01

7.  Thirty-four novel mutations detected in factor VIII gene by multiplex CSGE: modeling of 13 novel amino acid substitutions.

Authors:  D Habart; D Kalabova; M Novotny; Z Vorlova
Journal:  J Thromb Haemost       Date:  2003-04       Impact factor: 5.824

8.  Identification of 217 unreported mutations in the F8 gene in a group of 1,410 unselected Italian patients with hemophilia A.

Authors:  R Santacroce; M Acquila; D Belvini; G Castaldo; I Garagiola; S H Giacomelli; A M Lombardi; B Minuti; F Riccardi; R Salviato; L Tagliabue; E Grandone; M Margaglione
Journal:  J Hum Genet       Date:  2008-01-23       Impact factor: 3.172

  8 in total
  1 in total

1.  A Novel Missense Mutation, E1623G, in the Human Factor VIII Gene Associated With Moderate Haemophilia A.

Authors:  Habib Onsori; Mohammad Ali Hosseinpour Feizi; Abbas Ali Hosseinpour Feizi
Journal:  Iran Red Crescent Med J       Date:  2014-01-05       Impact factor: 0.611

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.